Off the wire
• Spotlight: U.S. braces for Trump's inauguration amid doubts, protests, partisan fights  • Constructive U.S.-Russia relations in world's interest: Obama  • NATO battalion to complete deployment in Latvia by June  • Jewelry worth 15 mln euros robbed in French city of Cannes  • Backgrounder: 10 key quotes from Xi's speech at UN Office at Geneva  • Pollution blamed for 30 to 35 pct of diseases in Macedonia: study  • Morocco's lower house approves constituent act of African Union  • Oil prices decline on rising U.S. production  • Suicide bombing in Mali "direct attack against peace process": UN peacekeeping chief  • 1st LD Writethru: Multinational battalion to begin deploying in Lithuania next week  
You are here: 　 Home

Novozymes announces layoff of 198 employees

Xinhua, January 19, 2017 Adjust font size:

Novozymes, the world's largest producer of industrial enzymes, announced on Wednesday that it will lay off 198 employees in January to safeguard profitablility.

In its 2016 annual report, the Copenhagen-based company said 62 of the laid-off employees are from Denmark, as the company seeks to "allocate additional resources to high-growth opportunities, primarily in emerging markets, while safeguarding profitability."

The company said it sees long-term opportunities within industrial biotechnology and will continue to invest in innovation to realize the potential of its pipeline.

"2017 will be a year with sustained investments in new innovation," said Peder Holk Nielsen, president and CEO of Novozymes. "The divisions have reviewed their strategies and made significant changes to accelerate growth, for example shifting more resources to the emerging markets."

"As a consequence, we unfortunately need to lay off 198 employees to enable investments in market opportunities in both 2017 and 2018," Nielsen said.

According to the report, the company's sales in 2016 grew by 2 percent organically from the previous year, primarily driven by Agriculture & Feed and Technical & Pharma.

Meanwhile, net profit in 2016 increased by 8 percent year-on-year to 3.05 billion Danish kroner (about 437 million U.S. dollars).

In 2017, Novozymes expects to deliver organic sales growth of 2 to 5 percent, with contributions from all five business areas.

Novozymes employs about 6,500 employees globally, and it has a market share around 48 percent. Enditem